Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556618 | 0.93 | REN (0.75) | RENKCNH2CYP3A4TAAR1PTGDR2 | |
| SCHEMBL556870 | 0.92 | REN (0.75) | RENKCNH2CYP3A4PTGDR2LMNA | |
| SCHEMBL534449 | 0.89 | REN (0.66) | RENKCNH2CYP3A4ALDH2PTGDR2 | |
| SCHEMBL534057 | 0.89 | REN (0.58) | RENKCNH2CYP3A4ALDH2 | |
| SCHEMBL10202576 | 0.85 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL557684 | 0.84 | REN (0.61) | RENKCNH2CYP3A4MTNR1AMTNR1B | |
| SCHEMBL535511 | 0.83 | REN (0.66) | RENKCNH2CYP3A4MTNR1AMTNR1B | |
| SCHEMBL556463 | 0.82 | REN (0.58) | RENKCNH2CYP3A4MTNR1AMTNR1B | |
| SCHEMBL557351 | 0.80 | REN (0.88) | RENKCNH2CYP3A4 | |
| SCHEMBL7869106 | 0.78 | REN (1.00) | RENKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1198/4885CYP3A4 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.